Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Immune escape by Epstein-Barr virus associated malignancies Munz C; Moormann ASemin Cancer Biol 2008[Dec]; 18 (6): 381-7Persistent Epstein-Barr virus (EBV) infection remains asymptomatic in the majority of virus carriers, despite the potent growth transforming potential of this virus. The increased frequency of EBV associated B cell lymphomas in immune compromised individuals suggests that tumor-free chronic infection with this virus is in part due to immune control. Here we discuss the evidence that loss of selective components of EBV specific immunity might contribute to EBV associated malignancies, like nasopharyngeal carcinoma, Burkitt's and Hodgkin's lymphoma, in otherwise immune competent patients. Furthermore, we discuss how current vaccine approaches against EBV might be able to target these selective deficiencies.|Antigens, Viral/immunology[MESH]|CD4-Positive T-Lymphocytes/immunology/virology[MESH]|CD8-Positive T-Lymphocytes/immunology/virology[MESH]|Cancer Vaccines/*immunology[MESH]|Epstein-Barr Virus Infections/complications/*immunology/virology[MESH]|HIV Infections/complications/immunology/virology[MESH]|Herpesvirus 4, Human/*immunology[MESH]|Humans[MESH]|Malaria, Falciparum/complications/immunology/parasitology[MESH]|Neoplasms/*immunology/parasitology/virology[MESH]|Tumor Escape/*immunology[MESH]|Virus Activation/immunology/physiology[MESH]|Virus Latency/immunology[MESH] |